FY2021 · ended Dec 31, 2021 · Revenue $351.37M, +622.5% YoY · Filed Feb 28, 2023
Atea Pharmaceuticals, Inc. (AVIR) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $219.5 million in cash and investments and $424,000 in total debt.
Revenue
$351.37M
+622.5% vs prior year
Net income
$-158.35M
+6.0% vs prior year
Operating cash flow (TTM)
$-152.07M
-30.1% vs year-ago TTM
Free cash flow
$-122.92M
-41.3% vs prior year
EPS
$-1.94
+3.0% vs prior year
Dividend per share
None
Shares outstanding
79.67M
-6.8% vs prior year
Net cash
$219.04M
as of Jun 30, 2026
Operating margin
39.4%
FY 2021
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVIR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1593899
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351.4M |
| Operating income | -$180.9M | -$192.9M | -$164.2M | -$130.7M | $138.4M |
| Net income | -$158.3M | -$168.4M | -$136.0M | -$115.9M | $121.2M |
| Diluted EPS | -$1.94 | -$2.00 | -$1.63 | -$1.39 | $1.37 |
| Operating cash flow | -$132.0M | -$135.5M | -$85.4M | -$121.0M | -$87.0M |
| Free cash flow | — | — | — | -$122.9M | -$87.0M |
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M |
| Stockholders' equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M |
| Cash and investments | $301.8M | $454.7M | $578.1M | $646.7M | $764.4M |
| Total debt | $843,000 | $1.6M | $2.4M | $3.1M | $197,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 10-K | Annual report | Mar 5, 2026 | Dec 31, 2025 |
All 313 Atea Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.